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P ulmonary artery (PA) hypertension (PAH) is characterized by a progressive increase in pulmonary vascular resistance and obliterative pulmonary vascular remodeling that result in right heart hypertrophy and failure and premature death. 1 The histopathological features of PAH include intima and media thickness, muscularization of distal PAs, vascular occlusion, and complex plexiform lesions. [2] [3] [4] [5] Owing to the poor understanding of the underlying mechanisms of obliterative vascular remodeling, current therapies targeting abnormalities in the prostacyclin, nitric oxide, and endothelin pathways result in only modest improvement in morbidity and mortality. [6] [7] [8] One of the major hurdles is the lack of appropriate murine models recapitulating the pathophysiology of severe PAH in patients, including idiopathic PAH (IPAH). 9, 10 Thus, identifying such genetically modified mouse model(s) and elucidating the molecular mechanisms of obliterative pulmonary vascular remodeling will provide valuable druggable targets and novel therapeutic approaches for the effective treatment of PAH in patients.
Clinical Perspective on p 2458
Hypoxia-inducible factors (HIFs) comprising an O 2 -sensitive α-subunit (mainly HIF-1α and HIF-2α) and a constitutively expressed β subunit are key transcription factors mediating adaptive responses to hypoxia and ischemia. 11, 12 As O 2 sensors, HIF prolyl-4 hydroxylases (prolyl hydroxylase domain-containing enzymes [PHDs] , also known as EGLN1-3) use molecular O 2 as a substrate to hydroxylate specific proline Background-Vascular occlusion and complex plexiform lesions are hallmarks of the pathology of severe pulmonary arterial hypertension (PAH) in patients. However, the mechanisms of obliterative vascular remodeling remain elusive; hence, current therapies have not targeted the fundamental disease-modifying mechanisms and result in only modest improvement in morbidity and mortality.
Methods and Results-Mice with Tie2Cre-mediated disruption of Egln1 (encoding prolyl-4 hydroxylase 2 [PHD2];
Egln1 Tie2 ) in endothelial cells and hematopoietic cells exhibited spontaneous severe PAH with extensive pulmonary vascular remodeling, including vascular occlusion and plexiform-like lesions, resembling the hallmarks of the pathology of clinical PAH. As seen in patients with idiopathic PAH, Egln1
Tie2 mice exhibited unprecedented right ventricular hypertrophy and failure and progressive mortality. Consistently, PHD2 expression was diminished in lung endothelial cells of obliterated pulmonary vessels in patients with idiopathic PAH. Genetic deletions of both Egln1 and Hif1a or Egln1 and Hif2a identified hypoxia-inducible factor-2α as the critical mediator of the severe PAH seen in Egln1 Tie2 mice. We also observed altered expression of many pulmonary hypertension-causing genes in Egln1
Tie2 lungs, which was normalized in Egln1
Tie2 /Hif2a Tie2 lungs. PHD2-deficient endothelial cells promoted smooth muscle cell proliferation in part through hypoxia-inducible factor-2α-activated CXCL12 expression. Genetic deletion of Cxcl12 attenuated PAH in Egln1
Tie2 mice. Conclusions-These studies defined an unexpected role of PHD2 deficiency in the mechanisms of severe PAH and identified the first genetically modified mouse model with obliterative vascular remodeling and pathophysiology recapitulating clinical PAH. Thus, targeting PHD2/hypoxia-inducible factor-2α signaling is a promising strategy to reverse vascular remodeling for treatment of severe PAH. (Circulation. 2016;133:2447-2458. DOI: 10.1161/CIRCULATIONAHA.116.021494.) [13] [14] [15] [16] Under hypoxic condition, inhibited PHD activity results in stabilization and accumulation of HIF-α in the nucleus. HIF-α and HIF-β form a heterodimer and activate expression of target genes that regulate angiogenesis, erythropoiesis, metabolism, inflammation, and vascular responses. 11, 12, 17 It has been shown that HIF-α activation plays an important role in the pathogenesis of pulmonary hypertension (PH). Hif1a +/− mice exhibited decreased PH whereas Hif2a +/− mice fail to develop PH in response to chronic hypoxia. 18, 19 Inactivation of Hif1a in smooth muscle cells (SMCs) in adult also attenuates hypoxiainduced PH. 20 An activating mutation of Hif2a induces PAH in mice and humans. 21, 22 The Vhl mutation also induces PH in mice and humans. 23, 24 However, little is known about the role of PHDs in the pathogenesis of PH. Pharmacological and genetic evidence has shown that PHD2 is responsible for the majority of HIF-α hydroxylation, whereas PHD1 and PHD3 play compensatory roles under certain conditions. [25] [26] [27] [28] [29] [30] Mice with inactivation of PHD2 are embryonic lethal, whereas PHD1-and PHD3-deficient mice are viable and normal.
27,28 siRNAmediated knockdown of PHD2, but not PHD1 or PHD3, leads to HIF stabilization in cell culture. 25 Thus, we set out to determine the fundamental role of PHD2 in regulating pulmonary vascular remodeling and the pathogenesis of severe PAH. We observed that PHD2 expression was diminished in endothelial cells (ECs) of obliterative pulmonary vessels of patients with IPAH. Using the mice with Tie2Cre-mediated disruption of Egln1 (encoding PHD2) in ECs and hematopoietic cells (HCs; Egln1 Tie2 ), we observed spontaneous severe PAH with extensive pulmonary vascular remodeling, including vascular occlusion and plexiform-like lesions, and severe right ventricular (RV) hypertrophy and right-sided heart failure. This phenotype is strikingly different from PH in mice induced by hypoxia alone or hypoxia and Sugen 5416 treatment. 17, [31] [32] [33] To the best of our knowledge, this is the first mouse model with irreversible obliterative vascular remodeling and pathophysiology as seen in patients with severe PAH, including IPAH. 9, 10, 32, 33 We identified HIF-2α (not HIF-1α) activation as the critical mediator of severe PAH downstream of PHD2 deficiency. We also showed that HIF-2α-mediated expression of CXCL12 (also known as stromal cell-derived factor 1α) in PHD2-deficient ECs promoted PA SMC proliferation and contributed to the pathogenesis of severe PAH in Egln1 Tie2 mice. 
Methods

Mice
Results
Loss of PHD2 in ECs and HCs Induces Severe PAH and Right-Sided Heart Hypertrophy and Failure
To gain insight into the role of PHD2 in the pathogenesis of PAH, we inactivated PHD2 in the mouse endothelium. Mice carrying an Egln1 gene in which exons 2 and 3 were flanked by 2 loxP sites were bred with Tie2 promoter/enhancer-driven Cre (Tie2Cre) transgenic mice to generate mice with Tie2Cre-mediated disruption of Egln1 (Egln1
Tie2
; Figure 1A ). Western blotting analysis showed that PHD2 expression was reduced >90% in lung ECs of Egln1 Tie2 mice ( Figure 1B ). Quantitative real-time reverse transcription-polymerase chain reaction (QRT-PCR) also revealed selective deletion of PHD2 in lung ECs but not fibroblasts ( Figure 1C ). Immunostaining demonstrated diminished PHD2 expression in pulmonary vascular ECs but not in bronchial epithelial cells in Egln1 Tie2 mice ( Figure 1D ). Together, these data demonstrate EC-specific deletion of PHD2 in Egln1
Tie2 mouse lungs. Immunostaining also showed loss of PHD2 expression in aortic ECs of Egln1 Tie2 mice ( Figure I in the online-only Data Supplement). Egln1 Tie2 mice were born normally in a mendelian ratio. To determine whether these mutant mice develop PAH, we measured RV systolic pressure (RVSP), which reflects PA systolic pressure.
Egln1
Tie2 mice had dramatically elevated RVSP that ranged from 60 to 90 mm Hg in mice 3.5 months of age ( Figure  1E and 1F). However, systemic blood pressure was normal ( Figure I in the online-only Data Supplement). Egln1
Tie2 mice also developed pronounced RV hypertrophy evident by the drastic increase in the weight ratio of RV to left ventricle (LV) plus septum (RV/LV+S), which averaged 0.9, a value not seen in other mouse PH models ( Figure 1G ).
Given that PAH induces RV hypertrophy and heart failure, we performed echocardiography to evaluate cardiac size and function in vivo. The RV chamber was markedly enlarged in Egln1
Tie2 mice but barely evident in WT mice (Figure 2A  and 2B ). Egln1
Tie2 mice exhibited marked RV hypertrophy as evidenced by a 3-fold increase in RV wall thickness ( Figure  2C ) and decreased RV contractility ( Figure 2D ). However, the LV cardiac size and function of Egln1 Tie2 mice were similar to those of WT mice ( Figure II in the online-only Data Supplement), suggesting that PAH in Egln1 Tie2 mice is not secondary to LV dysfunction. Egln1
Tie2 mice also exhibited a decreased ratio of PA acceleration time/ejection time ( Figure 2E ), indicating PA diastolic dysfunction. To determine whether Egln1
Tie2 mice develop right-sided heart failure, we assessed the expression of molecular markers of heart failure. 36, 37 QRT-PCR analysis revealed a marked increase in the expression of atrial natriuretic factor and skeletal α-actin ( Figure 2F ). Reactivation of this embryonic gene program is a common feature of heart failure. As seen in patients with IPAH, Egln1
Tie2 mice also exhibited progressive mortality; 80% of Egln1 Tie2 mice died by the age of 6 months ( Figure  2G ). Tie2 mice 3.5 months of age, 16% of the vessels were occlusive and 8% of large vessels (>100-μm diameter) exhibited plexiform-like lesions, including lesions with multi-CD31 + channels ( Figure 4C ). Prominent immunostaining of smooth muscle α-actin was evident in these lesions ( Figure 4D ). Immunostaining with anti-FSP1 (marker for fibroblasts) or anti-CD11b (marker for monocytes) demonstrated that the adventitia of these lesions was fibroblast enriched but with fewer CD11b-positive monocytes ( Figure 4E and 4F).
Increased Cell Proliferation in Pulmonary Vascular Lesions in Egln1
Tie2 Mice
We next determined whether vascular occlusion and formation of plexiform-like lesions in Egln1 Tie2 lungs were associated with abnormal vascular cell proliferation. Mouse lung sections were immunostained with anti-Ki67, a marker for cell proliferation, and anti-CD31 for ECs. As shown in Figure  4G , Ki67 staining was observed in pulmonary vascular ECs, SMCs, and adventitial cells in Egln1
Tie2 lungs but was not evident in control WT lung sections. Furthermore, Western Tie2 mice. Grade 1 (G1) indicates medial hypertrophy; G2, medial hypertrophy and intimal thickening (partial occlusion); G3, occlusive lesions (>75% occlusion); and G4, plexiform-like lesions. More severe pulmonary vascular remodeling was identified in Egln1 Tie2 mice at 3.5 compared with 1.5 months of age. Total indicates all vessels quantified (n=280 vessels per group, n=5 mice per group). In 3.5-month-old Egln1 Tie2 mice, plexiform-like lesions (G4) were seen mainly in large vessels (>100-μm diameter), whereas occlusive lesions (G3) were prominent in small vessels. blotting demonstrated a marked increase in the expression of proliferating cell nuclear antigen, a marker for cell proliferation in Egln1 Tie2 lung tissues ( Figure 4H ).
Diminished Expression of PHD2 in ECs of Occlusive Pulmonary Vessels in Patients With IPAH
To further determine the clinical relevance of our observations in Egln1 Tie2 mice, we assessed PHD2 expression in lung sections from patients with IPAH and normal donors. 35 PHD2 expression was diminished in the lumen (ECs) of occlusive pulmonary vessels of patients with IPAH ( Figure 5 ). However, nonocclusive pulmonary vessels from the same patients exhibited relatively normal PHD2 expression similar to that seen in the control samples ( Figure 5 ). These data suggest an important role for PHD2 deficiency in pulmonary vascular ECs in mediating obliterative vascular remodeling in patients.
HIF-2α Activation Secondary to PHD2 Deficiency Mediates PAH in Egln1
To determine the molecular basis of severe PAH in Egln1 Tie2 mice, we first analyzed HIF-1α and HIF-2α protein expression. Both proteins were markedly increased in Egln1
Tie2 lungs, a result consistent with PHD2 deficiency-induced stabilization ( Figure 6A ). We then generated EH1 and EH2 double-knockout mice by breeding Hif1a or Hif2a floxed mice with Egln1 Tie2 mice ( Figure 6B ). The RVSP and RV/LV+S ratio in EH2 mice were completely normal ( Figure 6C and 6D and Figure V in the online-only Data Supplement), whereas EH1 mice exhibited changes similar to those in Egln1 Tie2 mice ( Figure 6C and 6D) .
Echocardiography also revealed normal RV wall thickness, indicating no hypertrophy, and normal PA diastolic function evident by a normal value of the acceleration time/ ejection time ratio in EH2 mice ( Figure 6E and 6F) . EH2 mice at 3.5 months of age also exhibited normal pulmonary vascular pathology without evidence of vascular wall thickening, occlusion, or muscularization of the distal PAs ( Figure  6G-6I ). These data demonstrate that activation of HIF-2α (not HIF-1α) secondary to PHD2 deficiency is responsible for the obliterative vascular remodeling and severe PAH in Egln1 Tie2 mice.
Altered Expression of PH-Causing Genes in Egln1 Tie2 Lungs and Normalization in EH2 Lungs
To delineate the molecular signaling events that contribute to the severe PAH phenotype of Egln1 Tie2 mice downstream of HIF-2α, we performed whole-transcriptome RNA sequencing analysis ( Figure 7A-7E) . RNA sequencing data analysis showed upregulation of HIF-α target genes in Egln1
Tie2 lung, consistent with activation of HIF-α. Expression of some of them such as Arg1, Egln3, Serpine1, Pak6, Il6, Lox, and Nov was completely normalized in EH2 lungs, suggesting that these are HIF-2α target genes in Egln1
Tie2 lungs ( Figure 7B ). We also analyzed the expression profiles of genes involved in the pathogenesis of PH. Genes shown to be upregulated in various animal models of PH were markedly induced in Egln1 lungs. Expression of these genes was normalized in EH2 lungs ( Figure 7C ). Expression of genes known to be downregulated in published PH models was decreased in Egln1
Tie2 lungs and restored to levels either similar to or greater than that in WT lungs in EH2 mice ( Figure 7D and 7E) . QRT-PCR analysis confirmed marked changes in the expression of these genes in Egln1
Tie2 lungs, including increased expression of Slc39a12, Eln, Sphk1, Csf2, Cxcl12, Il6, and Edn1 and decreased expression of Ccr7, Apln, Aplnr, Cav1, Prkg1, Ccr2, and Bmpr2. Expression of these genes was normalized in EH2 lungs ( Figure 7F and 7G) . These data suggest that the complex pathology and severe PAH in Egln1
Tie2 mice are attributable to dysregulation of multiple signaling pathways secondary to PHD2 deficiency-activated HIF-2α.
PHD2-Deficient ECs Induce PA SMC Proliferation Partially Through HIF-2α-Dependent Release of CXCL12
Given that PA SMC proliferation plays an important role in pulmonary vascular remodeling, we next determined the role of PHD2 deficiency in ECs in directing PA SMC proliferation.
With the use of a coculture Transwell system, human lung microvascular ECs deficient in PHD2 induced by PHD2 siRNA-mediated knockdown ( Figure 8A) were plated in the top chamber, and human PA SMCs were cultured in the bottom chamber. As shown in Figure 8B and 8C, PHD2-deficient ECs induced a marked increase in SMC proliferation, suggesting that PHD2-deficient ECs play an important role in pulmonary vascular remodeling by directly releasing factor(s) to activate SMC proliferation.
We next explored the role of CXCL12 released by PHD2-deficient ECs in promoting SMC proliferation. As shown in Figure 8A , siRNA-mediated knockdown of PHD2 in human lung microvascular ECs induced a 5-fold increase in the expression of CXCL12. HIF-2α siRNA-mediated knockdown of HIF-2α inhibited PHD2 deficiency-induced CXCL12 expression, whereas HIF-1α knockdown had no effect, demonstrating that CXCL12 is an HIF-2α but not HIF-1α target gene in PHD2-deficient lung ECs. To determine whether induced CXCL12 expression contributes to SMC proliferation, we used siRNA to knock down CXCL12 in PHD2-deficient ECs ( Figure 8D) . A coculture experiment demonstrated that In Egln1 Tie2 lungs, we also observed a marked increase in CXCL12 expression compared with WT lungs that was inhibited in EH2 lungs but not in EH1 lungs (Figure 8E ), consistent with our observation in PHD2-deficient ECs described above. Thus, we generated a double-knockout mouse model with genetic deletions of both Egln1 and Cxcl12 by breeding Cxcl12 floxed mice into the genetic background of Egln1 Tie2 mice ( Figure 8F) . RVSP measurement revealed a marked decrease in PAH in Egln1
Tie2
/Cxcl12
Tie2 mice compared with Egln1 Tie2 mice ( Figure 8G ). RV hypertrophy was also markedly attenuated in these double-knockout mice ( Figure 8H ).
Together, these data demonstrate that HIF-2α-dependent activation of CXCL12 signaling contributes to the pathogenesis of severe PAH in Egln1 Tie2 mice ( Figure 8I ).
Discussion
The present study has demonstrated for the first time that genetic deletion of Egln1 in ECs and HCs induces spontaneous progressive PAH with severe vascular remodeling, including occlusion and complex plexiform-like lesions that resemble the pathology of clinical PAH. As seen in patients with IPAH, Egln1 Tie2 mice exhibit severe RV hypertrophy and failure and thus progressive mortality. We also observed dysregulated expression of multiple PH-causing genes in Tie2 lungs but inhibited expression in EH2 lungs identified by RNA-seq analysis. F, Quantitative real-time reverse transcription-polymerase chain reaction (QRT-PCR) analysis of expression of genes known upregulated in published PH animal models. Data are expressed as mean±SD (n=4 WT, 6 CKO, and 6 EH2). G, QRT-PCR analysis of expression of genes known to be downregulated in PH animal models. *P<0.05; **P<0.01; ***P<0.001. ANOVA followed by Games-Howell post hoc analysis was used for statistical analysis. 
Egln1
Tie2 lungs, and we demonstrated that CXCL12 induced in PHD2-deficient ECs promoted SMC proliferation. Inhibition of CXCL12 by Tie2Cre-mediated genetic deletion attenuated PAH in Egln1 Tie2 mice. These complex pathological and molecular changes in Egln1
Tie2 lungs are ascribed to HIF-2α activation. The observation that PHD2 expression is diminished in ECs of obliterative pulmonary vessels of patients with IPAH further demonstrates the clinical relevance of this model. These findings may lead to novel therapeutic strategies for the treatment of severe PAH, including IPAH, in patients.
Vascular occlusion and complex plexiform lesions are hallmarks of the pathology of severe PAH in patients. Although PAH in rats treated with the vascular endothelial growth factor receptor inhibitor Sugen 5416 and chronic hypoxia shows severe pulmonary vascular remodeling with stable vascular occlusion and plexiform-like lesions, 40, 41 obliterative vascular lesions in lungs of hypoxia/Sugen 5416-treated mice are not stable and resolved after 10 weeks of normoxic exposure. 33 A recent study also shows occlusive lung arterial lesions in a transgenic mouse model with inducible EC apoptosis. 42 However, the majority of these transgenic mice exhibit normal lung phenotype, and only a small proportion (21%) of them develop mild PAH with scarce occlusive lesions. Other genetically modified mouse models do not exhibit such complex vascular lesions.
9,10 RV hypertrophy is in general mild to median (RV/LV+S ratio, 0.3-0.5) in these alternative mouse models. Thus, no PAH mouse model recapitulates the complex pathology of clinical PAH in the literature.
9,10 Our study Tie2 lungs in an HIF-2α-but not HIF-1α-dependent manner. Lung tissues were collected from 1.5-month-old mice. F, Generation of a mouse model with genetic deletions of both Egln1 and Cxcl12 (ECx). G, ECx mice exhibited markedly decreased right ventricular (RV) systolic pressure (RVSP) compared with CKO mice (3.5 months old). H, RV hypertrophy was also partially inhibited in ECx mice. **P<0.01; ***P<0.001. ANOVA followed by GamesHowell post hoc analysis was used for statistical analysis in A, C, and E; the Student t test was used for statistical analysis in D, G, and H. I, A diagram showing the model that PHD2 deficiency in ECs and hematopoietic cells (HCs) induces obliterative pulmonary vascular remodeling and severe PAH. Endothelial PHD2 deficiency is essential for the development of PAH, whereas PHD2 deficiency in HCs promotes the severity of the disease. Through HIF-2α activation, PHD2 deficiency induces dysregulation of multiple signaling pathways in mouse lungs, which may act together to induce severe pulmonary vascular remodeling, including vascular occlusion and formation of plexiform-like lesions, as well as vasoconstriction and thus severe PAH and RV failure. provides unequivocal evidence that Tie2Cre-mediated disruption of Egln1 induces spontaneous severe PAH with characteristics of irreversible vascular occlusion and plexiform-like lesions. These mice exhibit a marked increase in RVSP ranging from 60 to 90 mm Hg and unprecedented RV hypertrophy with an average RV/LV+S ratio of 0.9. To the best of our knowledge, this is the first mouse model showing such great increases in RVSP and severe RV hypertrophy. Consistent with the progressive mortality seen in patients with IPAH, these mice also exhibit progressive mortality, and 80% of them die by 6 months of age. It is likely that these mice die of right-sided heart failure because they exhibit severe RV hypertrophy, decreased RV contractility, and reactivation of an embryonic gene program in the RV, a common feature of human heart failure. 36 G536W knock-in mice at 4-6 months, 42 mm Hg). There are no occlusive lesions but only a slight increase in small PA thickness in Vhl R200W mutation mice or Hif2a G536W knock-in mice. 22, 24 Intriguingly, the severe PAH phenotype in Egln1 Tie2 mice is ascribed to activation of HIF-2α but not HIF-1α. Both pathological and molecular changes in Egln1 Tie2 mice are normalized by genetic deletion of Hif2a. Consistent with our observation, previous studies have shown that heterozygous Hif2α deletion partially rescues Vhl R200W mutation-induced PAH. 24 Together, these studies point out an obligatory role of HIF-2α activation in the pathogenesis of PAH. Although HIF-1α and HIF-2α bind to an identical core sequence in hypoxia response element, they can activate distinct sets of genes. 43 Data from our RNA sequencing analysis show that the expression of some of the HIF-α target genes is dysregulated in Egln1
Tie2 mouse lungs but normalized by Hif2a deletion, suggesting that these are HIF-2α target genes, whereas a couple of them, Bnip3 and Pgk1, are more likely HIF-1α target genes. In human lung ECs, our data demonstrate CXCL12 as a target gene of HIF-2α. Additionally, HIF-2α is expressed predominantly in ECs, whereas HIF-1α is expressed more ubiquitously in almost all cell types. 44 Thus, HIF-2α may function differently from HIF-1α under various (patho)physiological conditions. Pulmonary endothelial dysfunction has been identified as a critical mediator of pulmonary vascular remodeling. Our coculture study provides clear evidence that PHD2-deficient ECs directly induce SMC proliferation, indicating the importance of endothelial cross talk with SMCs in the mechanisms of pulmonary vascular remodeling. We have identified CXCL12 as one of the factors released from PHD2-deficient ECs to induce SMC proliferation. The partial inhibition of SMC proliferation by CXCL12 knockdown in PHD2-deficient ECs suggests that other angiogenic factor(s) also contribute to EC-induced SMC proliferation. Consistent with our observation in vitro, genetic deletion of Cxcl12 results in a marked decrease in PAH in Egln1 Tie2 mice. Our data from RNA sequencing and QRT-PCR analysis demonstrate dysregulation of many PH-causing genes, including Edn1 (encoding endothelin-1) and Prkg1 (encoding protein kinase G), in Egln1 Tie2 lungs. Thus, it is unlikely to completely rescue the hypertensive pulmonary phenotype in Egln1
Tie2 mice by targeting a specific pathway downstream of PHD2/HIF-2α signaling.
These data also suggest the importance of combination therapy in the treatment of PAH in patients. 45 Another surprising finding is that PHD2 deficiency induced severe PAH but had no effects on systemic pressure. These differential effects of PHD2 deficiency are likely attributable to the marked difference of expression of PHD2 in the pulmonary vasculature compared with the systemic vasculature. PHD2 is highly expressed in pulmonary vascular ECs but more weakly expressed in systemic vascular ECs. Accordingly, PHD2 deficiency-induced expression of Cxcl12 and endothelin-1 in pulmonary vascular ECs and Egln1
Tie2 mouse lungs was not seen in Egln1 Tie2 mouse aorta. Besides the role of Cxcl12 in the development of severe PAH in Egln1
Tie2 mice, endothelin-1 is a potent vasoconstrictor, and clinical studies have demonstrated its role in the pathogenesis of PAH. Together, these data provide clear evidence of the differential effects of PHD2 deficiency on the pulmonary vascular system and systemic vasculature.
Our studies also demonstrate an important role of PHD2 deficiency in HCs in mediating the severe PAH phenotypes in Egln1 Tie2 mice. On one hand, WT chimeric mice reconstituted with Egln1
Tie2 bone marrow cells fail to develop PAH, indicating that PHD2 deficiency in bone marrow cells is not a prerequisite for the development of PAH. On the other hand, reconstitution of WT bone marrow cells in lethally irradiated Egln1 Tie2 mice attenuates PAH, indicating that Tie2Cre-meidated disruption of PHD2 in HCs contributes to the severity of PAH. These transplanted chimera experiments demonstrate the synergistic contribution of both endothelial and hematopoietic PHD2 deficiency to the severe PAH phenotype and complex pathology seen in Egln1 Tie2 mice. Prior studies also have demonstrated an important role of bone marrow abnormality associated with altered HIF signaling in the pathogenesis of clinical PAH. 46, 47 In addition, accumulating evidence shows that macrophages, T cells, and progenitor cells are recruited in the lesions, contributing to vascular remodeling. [47] [48] [49] It has also been shown that HIF-stimulated extracellular adenosine production and signaling affect the pathogenesis of PH through modulation of macrophage functional polarization. 50 Given the observation of induced CXCL12 expression in PHD2-deficient ECs, PHD2 deficiency in ECs may also promote bone marrow cell recruitment to the lung and thereby induce complex vascular remodeling. Thus, future studies are warranted to determine which bone marrow cell populations contribute to the severe
PAH phenotype in Egln1
Tie2 mice and whether PHD2-deficient EC-released CXCL12 or other chemokines promote bone marrow cell recruitment and thus contribute to the severity of PAH.
Conclusions
We have demonstrated for the first time that genetic deletion of Egln1 in ECs and HCs induces spontaneous progressive PAH with severe vascular remodeling, including occlusion and complex plexiform-like lesions, pronounced RV hypertrophy, and RV failure that resemble the pathology of clinical PAH. We also identify HIF-2α as a critical mediator of severe PAH seen in Egln1 Tie2 mice. The severe PAH phenotype characterized with complex obliterative vascular remodeling and dysregulation of various signaling pathways as seen in clinical PAH makes the Egln1
Tie2 mouse a unique and potentially useful mouse model for delineating the molecular mechanisms underlying the complex vascular remodeling of clinical PAH. Thus, targeting dysregulated PHD2-HIF-2α signaling may represent a novel effective therapeutic strategy to inhibit pulmonary vascular remodeling for the treatment of severe PAH, including IPAH, and thereby promote survival.
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CLINICAL PERSPECTIVE
Pulmonary arterial hypertension (PAH) is a progressive, fatal disease that without treatment leads to right-sided heart failure and death, often within 2 to 3 years of diagnosis. Owing to the poor understanding of the underlying mechanisms of obliterative vascular remodeling, current therapies result in only modest improvements in morbidity and mortality. One of the major hurdles is the lack of appropriate murine models recapitulating the pathophysiology of severe PAH in patients. In this study, we have demonstrated for the first time that genetic deletion of Egln1 in endothelial and hematopoietic cells induces spontaneous progressive PAH with severe pulmonary vascular remodeling, including occlusion and complex plexiform-like lesions that resemble the pathology of clinical PAH. As seen in patients with idiopathic PAH, Egln1
Tie2 mice exhibit severe right ventricular hypertrophy and failure and progressive mortality. We also observed dysregulated expression of multiple pulmonary hypertension-causing genes in Egln1
Tie2 lungs. These complex pathological and molecular changes in Egln1 Tie2 lungs are ascribed to hypoxia-inducible factor-2α activation. The severe PAH phenotype characterized by obliterative vascular remodeling and dysregulation of various signaling pathways as seen in clinical PAH makes the Egln1
Tie2 mouse a unique and potentially useful mouse model for delineating the molecular mechanisms underlying the complex vascular remodeling of clinical PAH. The observation that prolyl-4 hydroxylase 2 expression is diminished in endothelial cells of obliterative pulmonary vessels of patients with idiopathic PAH further demonstrates the clinical relevance of this model. Thus, targeting dysregulated prolyl-4 hydroxylase 2/hypoxia-inducible factor-2α signaling may represent a novel effective therapeutic strategy to reverse pulmonary vascular remodeling for the treatment of severe PAH, including idiopathic PAH, and promote survival. Mice were used for RVSP measurement and tissue collection at the age of 3.5 mo. To determine the efficacy of bone marrow cells reconstitution, bone marrow cells were isolated from the chimeric mice after RVSP measurement. Genomic DNA was extracted and used for QPCR analysis of Sry gene (a male-specific gene) as describe previously. 4 Autosomal gene Nme1 was used for internal control.
ONLINE METHODS
Echocardiography. Echocardiography was carried out in the Cardiovascular
Primary cultures of human lung microvascular ECs and pulmonary arterial SMCs.
Primary HMVEC-L cells (Lonza) were cultured as describe previously. 5 Briefly, HMVEC-L cells were cultured in T75 flasks precoated with 0.2% gelatin in EBM-2 medium supplemented with 15% FBS and EGM-2 MV Singlequots (Lonza), and maintained at 37 in a humidified atmosphere of 5% CO2. Cells between passage 4 and 7 were used for experiments. Primary human PASMCs (Lonza) were cultured in T75 flasks in SmGM-2 medium supplemented with 5%FBS and SmGM-2 SingleQuots (Lonza) under 5% CO2 incubator. PASMCs were used for experiments between 3 and 6 passages.
siRNA-mediated gene knockdown. HIF-1α siRNA was synthesized (Integrated DNA Technology) according to previous publication. 6 The other siRNA for EGLN1 (SI04188212), HIF2A (SI02663038) and CXCL12 (SI03649100) were obtained from Qiagen. Transfection of siRNA was performed using HMVEC-L Nucleofector kit (Lonza) with the Amaxa Nucleofector device (Lonza). For immunohistochemistry, slides were incubated with 6% H2O2 for 30 min after primary antibody incubation and were then biotinylated with a rabbit IgG and ABC kit (Vector Labs) for immunohistochemistry. The nucleus was co-stained with hematoxylin (Sigma-Aldrich).
For assessment of vascular remodeling, paraffin sections of mouse lungs were dewaxed and dehydrated, and then stained with a Russel-Movat pentachrome staining kit (American MasterTech) according to the manufacturer's protocol. 7, 8 RNA sequencing and bioinformatics analysis. RNA sequencing was carried out at the University of Chicago Genomics Facility. Briefly, RNA quality was checked on an Agilent Bioanalyzer. RNA-seq libraries were generated with TruSeq® Stranded Total RNA LT -(with RiboZero), RS-122-2301. All samples were sequenced with an Illumina Hiseq2500 with a single end 50-bp read length. For bioinformatics analysis, raw reads were trimmed to minimum Q20 using trimmomatic. 9 An initial alignment against mouse rRNA sequences using bowtie2 to remove any remaining ribosomal sequences was performed. We aligned the remaining reads with TopHat2 10 against the reference genome plus the transcriptome sequence by using UCSC Refseq annotations. Per-gene expression was quantified using CuffNorm 
